NRXP vs INMB vs SAVA vs PFE

For growth investors, INmune Bio, Inc.

(INMB) is the stronger pick with 257. 1% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Cassava Sciences, Inc. (SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: PFE returned +28. 5% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 49β versus INmune Bio, Inc. 's 2. 43β — meaning INMB is approximately 394% more volatile than PFE relative to the S&P 500. On balance sheet safety, INmune Bio, Inc. (INMB) carries a lower debt/equity ratio of 4% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INmune Bio, Inc.

(INMB) is pulling ahead at 257. 1% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, PFE leads at -14. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, PFE (6.

5% yield) pays a dividend. NRXP, INMB, SAVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 6. 5% yield). INmune Bio, Inc. (INMB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +28. 5%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NRXP is a small-cap quality compounder stock; INMB is a small-cap high-growth stock; SAVA is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while NRXP, INMB, SAVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.